Review of the ATHOS 3 trial
Northwestern EM Blog
FEBRUARY 14, 2022
The ATHOS-3 trial in 2017 explored the efficacy of angiotensin II as a vasopressor for severe vasodilatory shock. Severe shock is defined as persistent hypotension requiring vasopressors to maintain a mean arterial pressure of 65mmHg and serum lactate <2 despite adequate volume resuscitation. were more likely to respond.
52 
Let's personalize your content